A Phase II, Multicenter, Long-term Extension Study to Compare the Safety and Efficacy of TAK-385 (10, 20, and 40 mg) Following Oral Administration for 12 Weeks or More in the Treatment of Endometriosis

Trial Profile

A Phase II, Multicenter, Long-term Extension Study to Compare the Safety and Efficacy of TAK-385 (10, 20, and 40 mg) Following Oral Administration for 12 Weeks or More in the Treatment of Endometriosis

Completed
Phase of Trial: Phase II

Latest Information Update: 24 May 2017

At a glance

  • Drugs Relugolix (Primary) ; Leuprorelin
  • Indications Endometriosis
  • Focus Adverse reactions; Biomarker; Pharmacodynamics
  • Sponsors Takeda
  • Most Recent Events

    • 24 May 2017 According to a Myovant Sciences media release, results from the study were presented during a poster presentation at the 2017 European Congress of Endocrinology.
    • 24 May 2017 Results published in a Myovant Sciences media release.
    • 18 May 2017 According to a Myovant Sciences media release, 24 week extension data will be presented at the 19th European Congress of Endocrinology (ECE) 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top